CTE Blood Test: Two JAMA Studies Point to Detecting the Brain Disease in Living People
Researchers found that a tau protein fragment in blood tracked advanced chronic traumatic encephalopathy confirmed at autopsy. The test is not FDA-approved or available, and early-stage disease remains out of reach.
For two decades, chronic traumatic encephalopathy has carried a cruel rule: you can only know for certain after death. Families of former football players, boxers and combat veterans have watched mood swings, memory loss and personality changes unfold without a diagnosis, waiting for a brain autopsy to answer a question the living person never could. This month, two research teams published results in the Journal of the American Medical Association suggesting that a blood draw might one day tell doctors what only a pathologist can confirm today. One researcher called it “a game changer.” The same researchers also said, repeatedly, that it is not ready yet.
Why a Blood Test Would Change the Game for CTE
CTE is a degenerative brain disease linked to repeated head impacts, the kind delivered over years of tackling, boxing or exposure to blasts. Its hallmark is an abnormal buildup of tau protein in a pattern that differs from aging or Alzheimer’s disease. Symptoms can include changes in behavior and mood, problems with thinking and memory, and, over time, a gradual loss of movement control. Because the defining tau pattern is only visible under a microscope, doctors currently cannot confirm CTE in a living person.
That gap has practical consequences. Without a way to identify people with the disease while they are alive, researchers cannot easily enroll them in drug trials, track how the disease progresses, or test whether any treatment works. “If this study holds up with future research, if we validate it,” said Michael Alosco, co-director of clinical research at the Boston University CTE Center and co-senior author of one of the studies, the implications would be large. “This is a game changer,” he said.
Inside the Boston University and Banner Health Study
The study published on November 19, 2026, followed 21 former American football players who played at the professional, college and high school levels. All gave blood samples while alive and later donated their brains to the BU CTE Center’s brain bank. Banner Health’s Fluid Biomarker Program at the Banner Sun Health Research Institute in Sun City, Arizona, processed and analyzed the plasma.
When pathologists examined the brains, 18 of the 21 men had CTE. Sixteen had advanced disease, McKee stage 3 or 4, and two had low-stage disease, stage 1 or 2. Three had no CTE. Levels of the blood marker, endogenously cleaved microtubule-binding region tau, or eMTBR-tau, were significantly higher in players with high-stage CTE than in those with low-stage or no CTE. The protein was not elevated in either of those smaller groups.
Number of former football players by CTE status at autopsy. Source: Boston University and Banner Health, JAMA, November 19, 2026.
The marker was elevated only in the advanced-stage group, highlighted in magenta.
Nicholas Ashton, co-senior author and senior director of Banner’s Fluid Biomarker Program, compared the work to Alzheimer’s research, where blood tests now cleared by the FDA have been “revolutionary” for diagnosing patients and designing trials. “We are optimistic that the same will be true for CTE,” he said. The researchers cautioned that the blood test is not FDA-approved, is not publicly available, and should not be used for CTE diagnostic decisions until validation studies are complete.
A Second Team, a Larger Sample, a Similar Signal
A week earlier, on November 13, 2026, a team led by WashU Medicine in St. Louis and UCSF published a separate JAMA study using a closely related marker, eMTBR-tau243. The WashU group had previously shown that blood levels of this tau fragment reflect the buildup of tau tangles in Alzheimer’s disease. The new study asked whether it also rises in other “tauopathies,” the family of brain diseases defined by toxic tau.
The study included 229 participants drawn from several biorepositories, beginning with more than 80 people with autopsy-confirmed brain diseases plus healthy volunteers. The researchers then tested blood from 11 people whose CTE was confirmed at autopsy. Levels of eMTBR-tau243 were higher than in healthy people and rose with disease severity, but were much lower than in Alzheimer’s disease. The test distinguished advanced CTE from healthy people with high accuracy but could not reliably identify early-stage CTE.
Participants and autopsy-confirmed CTE cases in the two November 2026 JAMA studies. Sources: WashU Medicine and BU/Banner Health releases.
Together, the two studies include 29 autopsy-confirmed CTE cases.
“This is not going to be a standalone biomarker,” said Chihiro Sato, co-senior author of the WashU study. Her co-senior author, Kanta Horie, said, “We are potentially opening a new door for diagnosing and treating CTE in living patients.” WashU has licensed the eMTBR-tau243 blood test technology to C2N Diagnostics; the university and some authors disclosed financial interests in the company.
Comparing the Two Studies Side by Side
| Feature | BU and Banner Health | WashU Medicine and UCSF | What it means |
|---|---|---|---|
| Published in JAMA | November 19, 2026 | November 13, 2026 | Two independent groups, one week apart |
| Marker measured | eMTBR-tau | eMTBR-tau243 | Closely related tau fragments |
| Participants | 21 former football players | 229 from several brain banks | Both small for a diagnostic test |
| Confirmed CTE cases | 18 (16 advanced, 2 early) | 11 | Few early-stage cases in either |
| Main finding | Elevated only in high-stage CTE | Rises with severity; advanced CTE separated from healthy | Detects late, not early, disease |
| Key limitation | Small sample, no age-matched controls | Much lower levels than Alzheimer’s | Needs validation and other markers |
Compiled from the Boston University, Banner Health and WashU Medicine study releases, November 2026.
What We Know and What Remains Unproven
What We Know
- Two JAMA studies linked blood eMTBR-tau to autopsy-confirmed CTE.
- The signal was strongest in advanced CTE, stages 3 and 4.
- Neither study reliably detected early-stage CTE.
- The same marker is far higher in Alzheimer’s disease.
- No CTE blood test is FDA-approved or commercially available.
What Is Still Unclear
- Exact accuracy figures in larger, more diverse groups.
- Whether the test works in women, non-athletes and veterans.
- How early in the disease a blood marker could turn positive.
- Whether a five-year timeline to a commercial test is realistic.
The Alzheimer’s Problem: Why One Marker Is Not Enough
The biggest scientific hurdle is overlap. eMTBR-tau reflects tau tangles, and Alzheimer’s disease produces tau tangles too, at much higher levels. A raised result therefore does not neatly label a sample “CTE.” Alosco said the marker is elevated in both diseases, and other markers such as p-tau217, which tracks Alzheimer’s-type changes, would likely be needed to tell them apart.
Sato described how a future test might work in practice: a positive tau result in someone with a history of repeated head injury who tests negative for Alzheimer’s “might be CTE.” In other words, the blood test would be one piece of a diagnostic puzzle that also includes exposure history, symptoms, clinical exams and possibly brain imaging. The researchers proposed this combination; it has not been tested as a clinical pathway.
| Hypothetical result pattern | Tau marker | Alzheimer’s marker | Possible interpretation |
|---|---|---|---|
| Head-impact history, symptoms | High | Negative | May suggest advanced CTE, per researchers |
| Head-impact history, symptoms | High | Positive | Alzheimer’s likely; CTE cannot be separated |
| Head-impact history, symptoms | Normal | Negative | Does not rule out early CTE |
| No head-impact history | High | Positive | Points toward Alzheimer’s disease |
| No head-impact history | Normal | Negative | No tau signal detected |
Illustrative only, based on how study authors described potential future use. Not a validated diagnostic pathway.
Twenty Years of CTE Research, in Eight Snapshots
- 2005First published report of CTE in a former NFL player.
- 2017BU reports CTE in 110 of 111 former NFL players’ brains studied.
- 2018BU finds CTE in 1 of 164 Framingham community brains.
- 2021Consensus criteria define traumatic encephalopathy syndrome in life.
- 2023BU brain bank count reaches 345 of 376 former NFL players.
- 2025FDA clears the first blood test to aid Alzheimer’s diagnosis.
- Nov 13, 2026WashU and UCSF study of 229 people published in JAMA.
- Nov 19, 2026BU and Banner study of 21 donors published in JAMA.
Percent of brains with CTE. Sources: Boston University CTE Center (2017, 2023, 2018 Framingham comparison) and a Harvard-led study of 338 former NFL players reported in 2026. Brain bank samples are subject to selection bias and do not show true prevalence.
The spread in those numbers is itself a lesson. Brain banks such as BU’s receive brains disproportionately from families who saw symptoms, which inflates the rate. The BU CTE Center itself warns that its figures should not be read to mean that 91.7% of all current and former NFL players have CTE. A blood test, if validated, could finally let researchers measure how common the disease really is among living people.
A Worked Example: Why Accuracy Depends on Who Gets Tested
Even an accurate test can mislead when it is used on the wrong population. The numbers below are hypothetical, chosen only to show the arithmetic. Neither study published these accuracy figures.
Same test, two very different groups
- People tested10,000
- Actually have CTE100
- True positives at 90% sensitivity90
- False positives at 90% specificity990
- Chance a positive is realabout 8%
- People tested10,000
- Actually have CTE5,000
- True positives at 90% sensitivity4,500
- False positives at 90% specificity500
- Chance a positive is real90%
Hypothetical illustration of positive predictive value. Prevalence and accuracy figures are invented for the arithmetic and are not estimates of real CTE rates or test performance.
That is why researchers talk about using the test first in people at high risk who already have symptoms, such as former football players, boxers and combat veterans, rather than as a screening test for the public. It is also why a negative result would not rule out early disease, given that neither study could reliably detect low-stage CTE.
- Believing a CTE blood test is available now; it is experimental.
- Assuming a positive tau result means CTE; Alzheimer’s raises it far more.
- Reading brain bank rates as true prevalence among all NFL players.
- Expecting the test to catch early disease; both studies found it did not.
- Thinking CTE only affects pro players; donors included college and high school players.
What Former Players and Families Can Do Now
For people worried about their own brain health after years of contact sports or military blast exposure, the advice from researchers is to act on what is known today rather than wait for a future test. The Banner Health team recommended that anyone concerned see a clinician who specializes in neurodegenerative conditions and address modifiable risk factors that support brain health.
Write down your exposure: years of play or service, positions, and the number of diagnosed concussions.
Track symptoms over 3 to 6 months: mood, memory, attention, sleep and movement changes.
See a neurologist or memory clinic that evaluates traumatic encephalopathy syndrome.
Seek help immediately for thoughts of self-harm; call or text 988 in the U.S.
- Treat what can be treated now: depression, sleep apnea, headaches, blood pressure and hearing loss.
- Avoid offers of unvalidated “CTE tests”; none is approved.
- Ask about research studies that follow living participants with head-impact histories.
- Consider brain donation registration, which fuels studies like these two.
Because CTE cannot yet be confirmed in life, a 2021 consensus defined traumatic encephalopathy syndrome, or TES, as a clinical diagnosis based on substantial repeated head impacts plus core symptoms such as cognitive impairment or neurobehavioral changes. A future blood test could help link a TES diagnosis to the underlying CTE pathology.
WashU researchers said a validated blood test could enable trials of drugs that target harmful tau. Without a way to identify people with CTE while alive, no treatment can be properly tested, which is why both teams framed the test as a door to future therapies rather than a diagnosis on its own.
Frequently Asked Questions
Is there a blood test for CTE?
Not yet for clinical use. Two November 2026 JAMA studies found that a tau protein fragment in blood was elevated in people with advanced CTE confirmed at autopsy, but the test is experimental, not FDA-approved and not available to the public.
How is CTE diagnosed now?
CTE can be definitively diagnosed only after death, by examining brain tissue for a specific pattern of abnormal tau protein. In living people, doctors can diagnose traumatic encephalopathy syndrome based on head-impact history and symptoms.
What did the new CTE blood test study find?
In a Boston University and Banner Health study of 21 former football players, 18 had CTE at autopsy. Blood levels of eMTBR-tau were significantly higher in the 16 with advanced CTE than in those with early or no CTE.
When will a CTE blood test be available?
Researchers have said they hope a commercially available test could exist within about five years, but it first needs larger validation studies and regulatory review.
Can the CTE blood test detect early CTE?
Not reliably. Both studies found the marker was elevated mainly in advanced CTE, stages 3 and 4. Early-stage cases were few and were not reliably detected.
Why does Alzheimer’s complicate a CTE blood test?
The tau fragment measured is also elevated in Alzheimer’s disease, at much higher levels. Researchers expect a CTE test would need to be combined with Alzheimer’s markers and clinical history.
What percentage of NFL players have CTE?
No one knows the true rate. Boston University found CTE in 345 of 376 former NFL players’ brains studied, but its brain bank is subject to selection bias. A Harvard-led study of 338 former players found at least 1 in 4 had CTE.
Who is at risk of CTE?
People with repeated head impacts, including football players at all levels, boxers and military veterans exposed to blasts. Researchers say longer exposure is associated with higher risk.
The Two-Minute Drill
Two JAMA studies published in November 2026 found that a tau fragment in blood, eMTBR-tau, tracked advanced CTE confirmed at autopsy. The Boston University and Banner Health study involved 21 former football players; the WashU and UCSF study included 229 people, 11 with CTE. Both detected late-stage disease but not early CTE, and the marker is much higher in Alzheimer’s. Researchers call it a potential game changer for diagnosis and drug trials, hope for a commercial test within about five years, and stress that no CTE blood test is approved today.
Omisha is a health writer passionate about turning complex medical research into clear, actionable content readers can trust. She covers everything from nutrition and mental wellness to chronic disease management, always grounding her work in credible science and real-world relevance. When she's not writing, she's usually reading up on the latest health studies or exploring new wellness trends to write about next.
